Unlocking the Potential of Lutein and Zeaxanthin for Eye Health

Explore how the dietary supplements lutein and zeaxanthin can revolutionize visual performance and combat the onset and advancement of age-related macular degeneration (AMD), enhancing night, distance, close, and color vision.

Lutein and Zeaxanthin: Nature's Vision Protectors

Lutein and zeaxanthin are vital carotenoids, naturally occurring pigments found in the macula of the eye. Known as macular pigments or xanthophylls, they play a crucial role in protecting the retina and improving visual acuity. The scientific community has extensively researched their benefits, highlighting their significance in numerous clinical trials, including the ongoing AREDS2 study in the United States.

The Benefits of Lutein and Zeaxanthin Supplementation

  • Antioxidant and Photoprotective Qualities: Acting as natural sunblocks, these carotenoids protect the retina from excessive light and oxidative damage, potentially preventing AMD.
  • Enhanced Visual Performance: Supplementation has been shown to improve macular pigment optical density (MPOD), crucial for reducing AMD risk, stabilizing visual acuity, and enhancing the quality of life for patients with AMD.
  • Natural Sources: Found in dark green leafy vegetables, such as spinach and kale, and marigold flowers, these nutrients support eye health from within.

Clinical Evidence and Studies

Research indicates that a regular intake of lutein at 10 mg/day can bolster the eye's MPOD, offering a protective shield against AMD development. Patients with AMD who supplemented with lutein and zeaxanthin experienced notable improvements in visual functions, such as glare recovery, contrast sensitivity, and overall visual acuity.

Studies from China and other parts of the world corroborate these findings, suggesting that increased intake of lutein and zeaxanthin is associated with a diminished risk of AMD progression. These nutrients interact with the retina's proteins and lipids, modulate oxidative stress, and engage in signal transduction cascades essential for maintaining cellular health.

The Case for Supplementation

Despite the proven benefits of lutein and zeaxanthin, dietary intake of these carotenoids has been on the decline in Europe and the US. The average American consumes only about one to two mg of lutein daily, far below the recommended levels of 6 to 10 mg for optimal eye health. This gap underscores the importance of supplementing our diet with these crucial nutrients to ensure adequate intake and support for our visual system.

Conclusion: A Vision for Healthier Eyes

The evidence is clear: lutein and zeaxanthin are indispensable allies in the fight against age-related macular degeneration and other vision impairments. By incorporating these carotenoids into our daily regimen—either through diet or supplements—we can significantly enhance our eye health and safeguard our vision for years to come.

Remember, while supplements offer a valuable source of these nutrients, they should complement, not replace, a balanced diet. Consult with a healthcare professional before beginning any new supplement regimen, especially if you have existing health conditions or concerns. Together, let's embrace a future of brighter, healthier vision with the power of lutein and zeaxanthin.

Science References:
1- Johnson EJ, Chung HY, Caldarella SM, Snodderly DM. (2008). The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. Am J Clin Nutr 87:1521-529.
2- Chucair AJ, Rotstein NP, Sangiovanni JP, During A, Chew EY, Politi LE. (2007). Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid. Invest Ophthalmol Vis Sci 48:5168-5177.
3- Rotstein NP, Politi LE, German OL, Girotti R. (2003). Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. Invest Ophthalmol Vis Sci 44: 2252-2259.
4- Landrum JT, Bone RA, Kilburn MD. (1997). The macular pigment: a possible role in protection from age-related macular degeneration. Adv Pharmacol 38:537-556.
5- Huang LL, Coleman HR, Kim J, de Monasterio F, Wong WT, Schleicher RL, Ferris FL 3rd, Chew EY. (2008). Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Invest Ophthalmol Vis Sci 49:3864-3869.
6-Richer S, Devenport J, Lang JC. (2007). LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry (St Louis, Mo ) 78: 213-219.
7- Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. (2004). Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75:216-230.
8-Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, et al. (2007). Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res 84:718-728.
9- Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S; CARMIS Study Group. (2007). Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. – Ophthalmology 115: 324-333.e2.
10- Bahrami H, Melia M, Dagnelie G. (2006). Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial. BMC Ophthalmol 6:23-35.
11-Bartlett H, Eperjesi F. (2004). An ideal ocular nutritional supplement? Ophthalmic Physiol Opt 24:339-49.
12- Barker, FM. (2010) Dietary supplementation: effects on visual performance and occurrence of AMD and cataracts. Current Medical Research & Opinion 26: 2011–2023.

13- Beatty S, Chakravarthy U, Nolan JM, Muldrew KA, Woodside JV, Denny F, Stevenson MR. (2012). Secondary Outcomes in a Clinical Trial of Carotenoids with Coantioxidants versus Placebo in Early Age-Related Macular Degeneration. Ophthalmology pii: S0161-6420(12)00850-0. doi: 10.1016/j.ophtha.2012.08.040.

14- Aslam T, Delcourt C, Silva R, Holz FG, Leys A, Garcià Layana A, Souied E. (2012). Micronutrients in Age-Related Macular Degeneration. Ophthalmologica  DOI: 10.1159/000343708

15- Ma L, Dou HL, Huang YM, Lu XR, Xu XR, Qian F, Zou ZY, Pang HL, Dong PC, Xiao X, Wang X, Sun TT, Lin XM.. (2012). Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. Am J Ophthalmol. 154(4):625-634.e1. doi: 10.1016/j.ajo.2012.04.014.

16- Ma L, Yan SF, Huang YM, Lu XR, Qian F, Pang HL, Xu XR, Zou ZY, Dong PC, Xiao X, Wang X, Sun TT, Dou HL, Lin XM. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology. 119(11):2290-7. doi: 10.1016/j.ophtha.2012.06.014.

17- SanGiovanni JP, Neuringer M. (2012). The putative role of lutein and zeaxanthin as protective agents against age-related macular degeneration: promise of molecular genetics for guiding mechanistic and translational research in the field. Am J Clin Nutr. 2012 Nov;96(5):1223S-33S. doi: 10.3945/ajcn.112.038240.


Reading next

Leave a comment

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.